ValiRx (LSE:VAL) EPS (Basic) : £-0.02 (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is ValiRx EPS (Basic)?

ValiRx's basic earnings per share (Basic EPS) for the six months ended in Dec. 2023 was £-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.02.

ValiRx's EPS (Diluted) for the six months ended in Dec. 2023 was £-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.02.

ValiRx's EPS without NRI for the six months ended in Dec. 2023 was £-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -0.02.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

ValiRx EPS (Basic) Historical Data

The historical data trend for ValiRx's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx EPS (Basic) Chart

ValiRx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-0.33

-0.04

-0.02

-0.03

-0.02

ValiRx Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															-0.01	-0.02	-0.02	-0.01	-0.01

ValiRx EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

ValiRx's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.038	-	0)	/	101.570
	=	-0.02

ValiRx's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1.002	-	0)	/	102.332
	=	-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.02

ValiRx (LSE:VAL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

ValiRx EPS (Basic) Related Terms

Thank you for viewing the detailed overview of ValiRx's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx (LSE:VAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

EAJF:Germany

Address

4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.